BRAF V600E 突变在结直肠癌（CRC）中是一个重要的生物标志物，约占所有结直肠癌病例的 10%。这一突变通常与肿瘤的侵袭性、预后不良以及对常规化疗 ...

New York, USA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- BRAF Inhibitors Market to Register Incremental Growth During the Study Period (2020–2034) | DelveInsight The BRAF Inhibitors market is expected ...

Recombinant human TSH (rhTSH) was developed to provide TSH stimulation without the requirement for THST withdrawal and the ...

The three-drug regimen – based on Array BioPharma/Pierre Fabre’s BRAF inhibitor Braftovi (encorafenib) and MEK inhibitor Mektovi (binimetinib) along with Eli Lilly’s EGFR-targeted antibody E ...

Pfizer has announced that its Braftovi (encorafenib) regimen significantly improved both progression-free and overall survival in a late-stage colorectal cancer (CRC) study.

Doctors use targeted cancer drugs or immunotherapy to treat melanoma that has spread elsewhere in the body such as the liver, lungs or bone (advanced cancer). Or to treat stage 3 melanoma that cannot ...

In patients with metastatic colorectal cancer harboring a BRAF V600E mutation, the combo not only staved off disease progression but it also significantly extended patients’ lives compared with ...